Elevai Labs Inc (ELAB)

Mar 28, 2025, 8:00 AM EDT - 6 days ago

PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K

Mar 27, 2025, 8:00 AM EDT - 7 days ago

NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market

Mar 24, 2025, 5:00 PM EDT - 10 days ago

Univest Securities, LLC Announces Closing of $1.48 Million Registered Direct Offering for its Client PMGC Holdings Inc. (NASDAQ: ELAB)

Mar 21, 2025, 2:41 PM EDT - 13 days ago

PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules

Mar 21, 2025, 8:00 AM EDT - 13 days ago

PMGC Holdings Announces Share Repurchases from Existing Shareholders

Feb 27, 2025, 8:00 AM EST - 5 weeks ago

PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

Feb 26, 2025, 8:30 AM EST - 5 weeks ago

PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market

Feb 4, 2025, 8:00 AM EST - 2 months ago

Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1

Jan 31, 2025, 10:33 AM EST - 2 months ago

PMGC Capital LLC, a subsidiary of PMGC Holdings Inc., Begins to Build Portfolio with Strategic Acquisition of shares in U.S.-Focused Uranium Energy and Fire Prevention Technology Companies

Jan 28, 2025, 5:00 PM EST - 2 months ago

Univest Securities, LLC Announces Closing of $1.92 Million Warrant Inducement for its Client PMGC Holdings Inc. (NASDAQ: ELAB)

Jan 27, 2025, 9:00 AM EST - 2 months ago

PMGC Holdings Inc. Announces $1.9 Million in Gross Proceeds from Warrant Inducement with Institutional Investors

Jan 24, 2025, 8:00 AM EST - 2 months ago

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium

Jan 16, 2025, 8:31 AM EST - 2 months ago

PMGC Holdings Inc. Announces Closing of Elevai Skincare Divestiture

Jan 15, 2025, 9:30 AM EST - 2 months ago

PMGC Holdings Inc. Announces Name Change of Wholly Owned Subsidiaries

Jan 2, 2025, 3:55 PM EST - 3 months ago

PMGC Holdings Inc. Following Skincare Subsidiary Sale, Embarks on Bold Growth Strategy

Dec 20, 2024, 7:30 PM EST - 3 months ago

Elevai Labs Inc. Announces Name Change to PMGC Holdings Inc. and Redomicile to Nevada

Dec 20, 2024, 7:30 AM EST - 3 months ago

Elevai Labs Inc. Announces Anticipated Name Change to PMGC Holdings Inc. and Redomicile to Nevada

Dec 6, 2024, 7:30 AM EST - 4 months ago

Elevai Labs Inc. Subsidiary, Elevai Skincare, Launches S-Series Root Renewal System, Marking Entry into Hair Care Market

Nov 22, 2024, 6:23 PM EST - 4 months ago

Elevai Labs Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

Nov 22, 2024, 5:00 PM EST - 4 months ago

Elevai Labs Inc. Announces Withdrawal of Offer to Exchange and Plans to Reassess

Nov 14, 2024, 2:35 PM EST - 5 months ago

CORRECTION - Elevai Labs Inc.

Nov 14, 2024, 9:08 AM EST - 5 months ago

Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update

Nov 4, 2024, 5:45 PM EST - 5 months ago

Elevai Labs Inc. Announces Update and Extension of Pending Offer to Exchange

Oct 22, 2024, 9:54 AM EDT - 5 months ago

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity

Oct 21, 2024, 7:30 AM EDT - 5 months ago

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity

Oct 4, 2024, 5:08 PM EDT - 6 months ago

Elevai Labs Inc. Commences Offer to Exchange Up to 15,000,000 shares of Common Stock For Shares of Non Tradable. Locked Up Series B Preferred Stock

Oct 3, 2024, 3:45 PM EDT - 6 months ago

REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

Oct 3, 2024, 7:30 AM EDT - 6 months ago

Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations

Oct 2, 2024, 8:30 AM EDT - 6 months ago

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Launch of Clinical Study Combining Its Flagship Topical Exosome Skincare Products with a Medical Aesthetic Energy Device

Sep 24, 2024, 5:00 PM EDT - 6 months ago

Univest Securities, LLC Announces Closing of $8.0 Million Registered Follow-on Offering for its Client Elevai Labs Inc. (NASDAQ: ELAB)

Sep 23, 2024, 2:35 PM EDT - 6 months ago

Dow Gains Over 50 Points; Elevai Labs Shares Plummet

Sep 23, 2024, 8:45 AM EDT - 6 months ago

Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering

Sep 10, 2024, 7:30 AM EDT - 7 months ago

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications

Sep 3, 2024, 7:30 AM EDT - 7 months ago

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology

Aug 28, 2024, 7:30 AM EDT - 7 months ago

Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™

Aug 26, 2024, 7:30 AM EDT - 7 months ago

Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum

Aug 19, 2024, 9:00 AM EDT - 8 months ago

Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications

Aug 14, 2024, 9:05 AM EDT - 8 months ago

Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 30, 2024, 9:00 AM EDT - 8 months ago

Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD

Jul 16, 2024, 8:42 AM EDT - 9 months ago

Top 4 Risk Off Stocks You'll Regret Missing In July

EL MLEC

Jun 14, 2024, 9:00 AM EDT - 10 months ago

Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs

May 22, 2024, 4:15 PM EDT - 11 months ago

Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference

May 15, 2024, 4:30 PM EDT - 11 months ago

Elevai Labs Inc. Reports First Quarter 2024 Financial Results

May 2, 2024, 8:30 AM EDT - 1 year ago

Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity

May 1, 2024, 4:00 PM EDT - 1 year ago

Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare

May 1, 2024, 9:00 AM EDT - 1 year ago

Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments

Apr 29, 2024, 9:45 AM EDT - 1 year ago

Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments

Apr 22, 2024, 8:00 AM EDT - 1 year ago

ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months

Mar 29, 2024, 12:00 PM EDT - 1 year ago

Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results

Mar 18, 2024, 8:30 AM EDT - 1 year ago

Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market